

History of Research on Tumor Angiogenesis

Domenico Ribatti

History of Research on Tumor Angiogenesis

 Springer

Prof. Domenico Ribatti
Università di Bari
Policlinico
Dipartimento di Anatomia Umana e
Istologia
Bari
Italy
ribatti@anatomia.uniba.it

ISBN 978-1-4020-9559-7

e-ISBN 978-1-4020-9563-4

DOI 10.1007/978-1-4020-9563-4

Library of Congress Control Number: 2008940585

© Springer Science+Business Media B.V. 2009

No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.

Printed on acid-free paper

9 8 7 6 5 4 3 2 1

springer.com



Dedicated to the memory of Judah Folkman, a pioneer in the study of tumor angiogenesis

Contents

Chapter 1	1
1.1 Early Evidence of the Vascular Phase and Its Importance in Tumor Growth	1
1.2 Early Evidence of Tumor Cells Releasing Specific Growth Factor for Blood Vessels	2
1.3 Tumors in Isolated Perfused Organs: Absence of Angiogenesis ...	5
1.3.1 Hypothesis: Tumor Growth Is Angiogenesis-Dependent ..	6
1.3.2 Evidence that Tumors Are Angiogenesis-Dependent	6
1.4 The Avascular and Vascular Phases of Solid Tumor Growth	9
1.4.1 First Evidence of the Existence of the Avascular and Vascular Phases of Solid Tumor Growth	9
1.4.2 The Significance of Angiogenesis in Hematological Malignancies	10
1.4.3 Non-Angiogenesis-Dependent Pathways for Tumor Growth: Vascular Cooption and Vasculogenic Mimicry ..	15
Chapter 2	19
2.1 Isolation of the First Angiogenic Tumor Factor	19
2.2 The Discovery of Basic Fibroblast Growth Factor/Fibroblast Growth Factor-2	20
2.2.1 FGF-2 Receptors and FGF-2 Interactions	21
2.2.2 The Role of FGF-2 in Tumor Growth and Vascularization	22
2.3 The Discovery of Vascular Permeability Factor/Vascular Endothelial Growth Factor	23
2.3.1 The Contribution of Harold F. Dvorak. Tumor Blood Vessels Are Hyperpermeable to Plasma Proteins and to Other Circulating Macromolecules	23
2.3.2 The Contribution of Napoleone Ferrara	26
2.3.3 The Discovery of Angiopoietins	29
Chapter 3	31
3.1 How Do Tumor Cells Switch to the Angiogenic Phenotype?	31
3.2 The Concept of Angiogenic Switch	32

3.3	Factors Involved in the Angiogenic Switch	33
3.4	What Is the Evidence that Genetic Instability Promotes the Angiogenic Switch?	34
3.4.1	The RIP1-TAG2 Model	35
3.4.2	The K14-HPV16 Model	37
3.4.3	The Papilloma Virus Type 1 Model	38
Chapter 4	41
4.1	Tumor Endothelial Cell's Features	41
4.2	Tumor Basement Membrane	43
4.3	Tumor Pericytes	43
Chapter 5	47
5.1	Tumor Lymphangiogenesis	47
Chapter 6	53
6.1	The Contribution of Inflammatory Cells to Tumor Angiogenesis ..	53
6.1.1	Neutrophils	54
6.1.2	Monocytes and Macrophages	56
6.1.3	Lymphocytes	59
6.1.4	Eosinophils	59
6.1.5	Mast Cells	60
Chapter 7	63
7.1	The Role of Endothelial Progenitor Cells in Tumor Angiogenesis. The First Isolation of Putative Endothelial Progenitor Cells	63
7.2	Characterization of Endothelial Progenitor Cells	63
7.3	Triggers and Inhibitors of Endothelial Progenitor Cells to Sites of Active Neovascularization	64
7.4	The Transplantation Models to Study Endothelial Progenitor Cells	65
7.5	The Identification of Bone Marrow-Derived Multipotent Progenitor Cells	66
7.6	Monocyte/Macrophage as a Source of Endothelial Progenitor Cells	67
7.7	Contribution of Endothelial Progenitor Cells to Tumor Angiogenesis	67
Chapter 8	71
8.1	Tumor Microvascular Density as a Prognostic Indicator	71
8.2	Use of Panendothelial Cell Markers	72
8.3	Topography	74
8.4	Certain Human Tumor Types Can Exhibit Lower Microvascular Density than the Corresponding Normal Tissues	74
8.5	Prognostic Value of Microvascular Density	75
8.6	The Relationship Between Microvascular Density and Intercapillary Distance	75

- Chapter 9** 77
- 9.1 Inhibitors of Angiogenesis 77
 - 9.1.1 Interferons 79
 - 9.1.2 Cartilage 80
 - 9.1.3 Protamine and Platelet Factor 4 81
 - 9.1.4 Vascular Disrupting Agents 81
 - 9.1.5 Angiostatic Steroids 82
 - 9.1.6 Fumagillin 83
 - 9.1.7 Thrombospondin-1 83
 - 9.1.8 Angiostatin and Endostatin 84
 - 9.1.9 Thalidomide 86
- 9.2 Metronomic Chemotherapy 87
- 9.3 Receptor Tyrosine Kinase (RTK) Inhibitors 89
- 9.4 Inhibitors of VEGF 90
- 9.5 Antiangiogenic Monoclonal Antibodies: Toward the Discovery of Avastin 91
- 9.6 Microvascular Density Has Not Been Shown to Be a Valid Measurement to Guide or Evaluate Antiangiogenic Treatment 94
- 9.7 Perspectives 95
- References** 99